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Adenosine 50-monophosphate (AMP)-activated protein kinase (AMPK) is a key player in regulating energy
metabolism, placing it at the center stage in studies of diabetes and related metabolic diseases. Expressed
in key metabolically relevant organs, AMPK is activated in response to a variety of stimuli, including cellular
stress, exercise, and a wide range of hormones and agents that exert impacts on cellular metabolism.
Genetic and pharmacological studies demonstrate that AMPK is required for maintaining glucose homeo-
stasis. Activation of AMPK by pharmacological agents presents a unique challenge, given the complexity
of the biology, but holds a considerable potential to reverse the metabolic abnormalities associated with
type 2 diabetes.Introduction
According to National Diabetes Statistics, the number of people
with diagnosed and undiagnosed diabetes in the United States
reached 23.6 million, which is 7.8% of the general population,
in 2007. The total number of people worldwide with diabetes
is projected to rise to 366 million in 2030. A number of thera-
peutic agents exist for the treatment of type 2 diabetes mellitus
(T2DM), including metformin, sulfonylureas, DPP-4 inhibitors,
PPARg agonists, a-glucosidase inhibitors, insulin, and GLP-1
analogs. However, in addition to inadequate efficacy and dura-
bility, some of these agents suffer from liabilities, including hypo-
glycemia, weight gain, edema, fractures, lactic acidosis, and
gastrointestinal intolerance (Nathan et al., 2009). In aggregate,
there is a pressing need to develop novel modalities for the treat-
ment of diabetes to stem the spread of this global epidemic.
AMP-activated protein kinase (AMPK) is a potential target for
novel agents that may meet this challenge.
AMPK is a major cellular energy sensor and a master regulator
of metabolic homeostasis. AMPK is a heterotrimeric enzyme
comprised of a catalytic (a1 or a2) subunit and two regulatory
(b1 or b2 and g1, g2, or g3) subunits, all of which are encoded
by separate genes, making it possible to form a total of 12
complexes (Hardie, 2008) (Figure 1). AMPKs are activated by
two distinct signals: a Ca2+-dependent pathway mediated by
CaMKKb and an AMP-dependent pathway mediated by LKB1
(Sanders et al., 2007b). These and other upstream kinases,
includingTGF-b-activatedkinase-1 (Tak1), phosphorylateThr172
on the a subunit. Binding of AMP to the g subunit leads to allo-
steric activation of AMPK as well as protection of Thr172 from
dephosphorylation, thereby maintaining the enzyme in the acti-
vated state. AMPK thus serves as a unique metabolic control
node as it senses cellular energy status through modulation
of its activities via phosphorylation and allosteric activation
by AMP. Activation of AMPK by Tak1 leads to cytoprotective
autophagy in untransformedcells against TNF-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis (Herrero-Martin et al.,
2009).
A number of physiological processes have been shown to
stimulate AMPK, including conditions that lead to alterations ofthe intracellular AMP/ATP ratio (e.g., hypoxia, glucose depriva-
tion) and calcium concentration, as well as the action of various
hormones, cytokines, and adipokines. The activated form of the
enzyme is responsible for metabolic changes via phosphoryla-
tion of various downstream substrates. The net effect is a change
in local and whole-body energy utilization from an energy-
consuming state to an energy-producing state in order to restore
energy balance. These findings, coupled with reports that AMPK
in muscle is activated in response to exercise (Long and Zierath,
2006; Reznick and Shulman, 2006), have led to an intense
interest in developing AMPK activators as potential therapies
for T2DM and obesity (Hardie, 2008).
The effects of AMPK activation are pleiotropic in key metabol-
ically relevant tissues, such as liver, skeletal muscle, adipose,
and hypothalamus. In this review, we will focus the discussion
on the beneficial effects of AMPK activation in liver and muscle
on modulation of insulin sensitivity and energy homeostasis.
We will explore key issues and challenges that need to be
addressed in the pursuit of AMPK activators for the treatment of
diabetes, obesity, and related metabolic diseases.
Role of AMPK Activation in Countering Liver andMuscle
Insulin Resistance
In T2DM, the major insulin-resistant organs include liver, muscle,
andadipose tissue. Ina stateof insulin resistance, glucoseuptake
and utilization are dramatically decreased, and skeletal muscle
becomes metabolically inflexible, unable to switch between
glucose and fatty acid use (Kelley et al., 1999). More recently,
defects in fatty acid oxidation have been considered the primary
causal factors in the development of muscle insulin resistance
(Petersen et al., 2004).While deficiencies in skeletal musclemito-
chondrial capacity and fatty acidmetabolismmay be responsible
for intramyocellular lipid accumulation leading to an insulin-resis-
tant state (Petersen et al., 2004), it is important to point out that
incomplete fatty oxidation and mitochondrial overload also
contribute to skeletal muscle insulin resistance (Koves et al.,
2008), considering that the capacity of muscle to oxidize
substrate is far in excess of what is needed to supply energy to
resting muscle (Holloszy, 2009).Cell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc. 407
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Liver AMPK controls glucose homeostasis mainly through the
inhibition of gluconeogenic gene expression and hepatic glucose
production. In primary hepatocytes, AMPK activation mediated
by both AICAR (5-aminoimidazole-4-carboxamide-1-b-D-ribo-
furanoside [see below]) and metformin has been demonstrated
to downregulate PEPCK and G6Pase (Lochhead et al., 2000;
Zhou et al., 2001). Expression of PEPCKandG6Pase are induced
by transcription factor binding to the cAMP-responsive element
(CRE) of these genes involving CRTC2 (CRE-binding protein
[CREB]-regulated transcription coactivator 2) and FOXO1 (fork-
head box O1), both of which are suppressed by AMPK (Liu
et al., 2008). CRTC2 also drives the expression of PPARg coacti-
vator 1a (PGC-1a), which in turn increases gluconeogenesis
(Shaw et al., 2005). In addition, AMPK activation increases phos-
phorylation of GSK-3b (glycogen synthase kinase 3b) and
thereby reduces CRE transcriptional activity and PEPCK-C
gene expression in the liver, reducing gluconeogenesis (Horike
et al., 2008).
Glucose production in primary cultured hepatocytes was sup-
pressed by both metformin (Zhou et al., 2001) and an adipokine,
adiponectin (Yamauchi et al., 2002), as well as by adenovirus
expressing a constitutively active form of AMPKa2 (Foretz
et al., 2005). In animal models, infusion of AICAR suppressed
endogenous hepatic glucose production and lowered plasma
glucose (Bergeron et al., 2001). In diabetic patients, the glucose-
lowering effect of metformin is at least partly attributed to its
ability to suppress gluconeogenesis (Hundal et al., 2000). The
effect of metformin on AMPK activation and glucose lowering
was abolished in LKB1/ mice (Shaw et al., 2005), demon-
strating the importance of LKB1, the major kinase of AMPK in
liver, in glucose control by this drug.
Figure 1. Activation of AMPK by Upstream
Kinases and the Potential Beneficial
Consequences
LKB1 is activated by an increase of the AMP/ATP
ratio, while CAMKK is activated by an increase in
intracellular Ca2+. Both LKB1 and CAMKK phos-
phorylate AMPK on Thr172. The key substrates
of AMPK as well as the consequences of AMPK
activation are indicated. FAO, fatty acid oxidation;
HGO, hepatic glucose output; GNG, gluconeo-
genic genes.
Liver AMPK also decreases hepatic
lipogenesis. AMPK phosphorylates and
inactivates acetyl-CoA carboxylase 1
(ACC1) and 3-hydroxy-3-methylglutaryl-
CoA reductase, leading to inhibition of de
novo fatty acid and cholesterol synthesis.
Phosphorylation of ACC2 by AMPK, on
the other hand, causes increases of fatty
acid oxidation (Viollet et al., 2009). ACC
is a rate-determining enzyme for the
synthesis of malonyl-CoA, both a critical
substrate for fatty acid biosynthesis and
a potent inhibitor of fatty acid oxidation
(Figure 2). AMPK can also increase the
activity of malonyl-CoA decarboxylase
(MCD) (Assifi et al., 2005) to further decrease hepatic malonyl-
CoA levels. Hypertriglyceridemia has been documented in both
whole-body AMPKa2/ and liver-specific AMPKa2/mice (An-
dreelli et al., 2006). In addition, AICAR infusion has been shown to
decrease plasma TG (Bergeron et al., 2001). AMPK alsomediates
suppression of lipogenic gene expression (fatty acid synthase
[FAS]andACC)viadecreasing theactionsof transcriptional factors
SREBP-1c (Foretz et al., 2005; Zhou et al., 2001) and ChREBP
(Kawaguchi et al., 2002). AMPK inactivates mitochondrial glyc-
erol-3-phosphate acyltransferase (mtGPAT) (Muoio et al., 1999),
providing a means to reciprocally regulate acyl-CoA channeling
toward b-oxidation and away from glycerolipid biosynthesis.
AMPK Action in Muscle
Muscle AMPK is activated during contraction and may mediate
multiple beneficial effects of exercise.As in the liver, acutemuscle
AMPK activation increases fatty acid oxidation by decreasing
malonyl-CoA concentrations though inhibiting ACC and acti-
vating MCD. Increased mitochondrial fatty acid oxidation results
in decreased intramyocyte lipid accumulation and increased
muscle insulin sensitivity (Ruderman et al., 2003). Chronicmuscle
AMPK activation, by exercise training and by AICAR treatment,
can further enhance muscle lipid breakdown and the capacity
for ATP generation by transcriptional activation of mitochondrial
fatty acid b-oxidation enzymes via PGC-1a (Suwa et al., 2003).
Mediation of glucose uptake by both muscle contraction and
AMPK activation is insulin independent and additive with the
effects of insulin. Studies have shown that the capacity for
AMPK-mediated glucose uptake is intact in muscle cells from
patients with T2DM, while insulin-induced glucose uptake is
impaired (Koistinen et al., 2003). Similar to a single bout of exer-
cise, the insulin sensitivity of muscle, liver, and whole body was
increased 24 hr after a single dose of AICAR in a high-fat-fed408 Cell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc.
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stimulates phospho-Akt substrate (PAS)-TBC1D1 and glucose
transport but not PAS-TBC1D4 (also referred to as Akt substrate
of 160 kDa [AS160]) in an AMPK-dependent manner (Funai and
Cartee, 2009). Chronic AMPK activation has been shown to
increase muscle Glut4, hexokinase, and glycogen content in
skeletal muscle, similar to the effects of endurance training
(Holmes et al., 1999).
AMPK activation has been shown to increase mitochondrial
genes in skeletal muscle via PGC-1a induction (Jager et al.,
2007). In parallel, AMPK increases cellular NAD(+) levels and
enhances sirtuin 1 (SIRT1) activity, resulting in the deacetylation
and activation of PGC-1a (Canto et al., 2009). Both insulin resis-
tance and metabolic inflexibility are associated with muscle
mitochondrial dysfunction in type 2 diabetic and obese subjects
(Kelley et al., 2002), suggesting that AMPK-mediated mitochon-
drial improvement may overcome the metabolic inflexibility as
well as insulin resistance. Indeed, 4 weeks of AICAR treatment
was sufficient to induce genes involved in muscle metabolism
and to enhance running endurance in sedentary mice (Narkar
et al., 2008). In muscle-specific transgenic mice expressing an
inactive form of the AMPKa2 catalytic subunit, the lack of skel-
etal muscle AMPKa2 activity exacerbated the development of
glucose intolerance and insulin resistance caused by high-fat
feeding (Fujii et al., 2008), suggesting a key role of AMPKa2 in
glucose homeostasis.
Taken together, activation of AMPK in the liver and muscle is
expected to elicit a spectrum of beneficial metabolic effects
with the potential to ameliorate the defects associated with
T2DM and the metabolic syndrome.
Other AMPK Substrates
In addition to the well-known AMPK substrates ACC and HMG-
CoA reductase, many other substrates of AMPK are also docu-
mented.Oneexample ishistonedeacetylase (HDAC)5.Phosphor-
ylation of HDAC5, a transcriptional repressor, causes HDAC5 to
associate with 14-3-3. HDAC5 is then acetylated and falls off
Figure 2. Schematic Diagram of Lipid
Metabolism and the Regulation by AMPK
AMPK phosphorylates ACC1/2 and mtGPAT, in-
hibiting lipogenesis; AMPK activates MCD,
reducing the levels of malonyl-CoA, thus inhibiting
the substrate supply of lipogenesis. Reduction of
malonyl-CoA also relieves CPT1 inhibition,
increasing lipid oxidation.
from GLUT4 promoter and exits the
nucleus. The net result of AMPK activation
is increased Glut4 transcription (McGee
et al., 2008). This and other yet to be
discovered actions of AMPK will further
broaden our understanding of the biolog-
ical consequences of AMPK activation.
Activation of AMPK by Indirect
Activators
A number of hormones and pharmaco-
logical agents have been reported to acti-
vate AMPK in vivo or upon treatment of cells and/or tissues
(Figure 3). While the detailed modes of action by which these
agents activate AMPK are not fully delineated, they act in an indi-
rect manner. Changes in mitochondrial coupling and cellular
energy state could account for, at least in part, the mechanisms
leading to cellular AMPK activation. Studies using these agents
have aided our understanding of the role of AMPK in the regula-
tion of cellular processes and whole-body energy homeostasis.
Metformin
Metformin is an antihyperglycemic agent with effects on sup-
pressing hepatic glucose output. In 2001, it was reported that
metformin activatedAMPK inhepatocytes, reducingACCactivity
and inducing fatty acid oxidation (Zhou et al., 2001), thus linking
metformin action to AMPK activation. SREBP-1, a key lipogenic
transcription factor, was reduced at both mRNA and protein
levels in cells following metformin treatment. Metformin requires
LKB1, which phosphorylates and activates AMPK in the liver to
lower blood glucose levels (Shaw et al., 2005). These studies
strongly suggest that activation of AMPK provides a unified
explanation for the pleiotropic beneficial effects of metformin.
Correlative results were also observed with respect to metformin
increasing AMPK activity in skeletal muscle of subjects with type
2 diabetes (Musi et al., 2002).
Thiazolidinediones (TZDs)
TZDs are activators of PPARg and function as insulin sensitizers.
Incubation of isolated rat EDL muscles in culture medium con-
taining 5 mM troglitazone for 15 min (a time course too brief to
be attributable to transcriptional effects) significantly increased
phosphorylation of AMPK and ACC, paralleled by a transient
increase in the AMP/ATP ratio (LeBrasseur et al., 2006). In clamp
studies, rosiglitazone treatment significantly enhanced AICAR-
stimulated whole-body glucose disposal (Ye et al., 2006), sug-
gesting that TZDs can activate AMPK by a mechanism that
is likely independent of PPARg-regulated gene transcription.
However, the major effect of TZDs is likely to be on the release
of adiponectin by adipocytes, leading to activation of AMPK in
liver to reduce glucose production (Kubota et al., 2006).Cell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc. 409
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Full-length adiponectin induces phosphorylation and activation
of AMPK in skeletal muscle and liver, increasing phosphorylation
of ACC and fatty acid oxidation, enhancing glucose uptake and
lactate production in myocytes, and reducing glucose levels
in vivo (Yamauchi et al., 2002). The requirement of AMPK activa-
tion in mediating the adiponectin effects was confirmed by
blocking AMPK activation with dominant-negative mutants of
AMPK, which inhibited the stimulation of glucose utilization
and fatty acid oxidation by adiponectin. Insulin but not adiponec-
tin totally inhibited endogenous glucose production in liver-
specific AMPKa2/ mice, further demonstrating the role of
AMPK in adiponectin action (Andreelli et al., 2006).
Leptin
Leptin selectively stimulates phosphorylation and activation of
the a2 catalytic subunit of AMPK in skeletal muscle. It was re-
ported that early activation of AMPK occurred by leptin acting
directly onmuscle, whereas the later-phase activation depended
on leptin functioning through the hypothalamic-sympathetic
nervous system axis (Minokoshi et al., 2002). In addition to
AMPK phosphorylation, leptin also induced PPARa gene tran-
scription in C2C12 cells. In these cells, the a2b1-containing
AMPK complexes resided in the cytoplasm and phosphorylated
ACC, leading to increases in fatty acid oxidation. In contrast,
a2b2-containing AMPK complexes underwent translocation to
the nucleus, where they induced PPARa gene transcription. A
nuclear localization signal and Thr172 phosphorylation of a2
were found to be essential for nuclear translocation of AMPKa2,
whereas the myristoylation of b1 anchored AMPKa2 complex in
the cytoplasm (Suzuki et al., 2007).
Ciliary Neurotrophic Factor (CNTF)
CNTF signals through the CNTFRa-IL-6R-gp130b receptor
complex to increase fatty acid oxidation and improve insulin
sensitivity in skeletal muscle by activating AMPK, independent
of signaling through the brain (Watt et al., 2006). Intraperitoneal
injection of a second-generation CNTF analog, CNTF(Ax15),
reduced hypothalamic AMPKa2 activity, AMPKa2 Thr172 phos-
phorylation, and ACC phosphorylation in both lean mice as well
as diet-induced-obesity mice. Intracerebroventricular injection
Figure 3. Modulators of AMPK Activation
Exercise and the agents listed have been shown to modulate
the activity of AMPK. See text for more details.
of CNTF(Ax15) reduced AMPK signaling and food
intake, an effect possibly mediated by the arcuate
nucleus. These studies suggest that CNTF(Ax15)
bypasses diet-induced leptin resistance to reduce
hypothalamicAMPKactivity (Steinberg et al., 2006).
Ghrelin/Cannabinoids
Both endocannabinoids and ghrelin are potent
appetite stimulators that increase AMPK activity
in the hypothalamus and the heart while inhibiting
AMPK in liver and adipose tissue, which may
contribute to the well known effects of endocanna-
binoids and ghrelin on the metabolism of peripheral
tissues, including the reduction in infarct size in the
myocardium, the enlargement in adipose tissue,
and changes in carbohydrate and lipid metabolism (Kola et al.,
2005). Pharmacological and genetic approaches reveal that
the physiological orexigenic response to ghrelin involved activa-
tion of AMPK in the CNS, leading to inhibition of fatty acid
biosynthesis via ACC inhibition, decreases in hypothalamic
levels of malonyl-CoA, and the resulting increases in carnitine
palmitoyltransferase 1 (CPT1) activity (Lopez et al., 2008). Ghre-
lin increased the endocannabinoid content of hypothalamus.
Since ghrelin did not induce an orexigenic effect in CB1
knockout mice, an intact cannabinoid signaling pathway is
necessary for the stimulatory effects of ghrelin on AMPK activity
and food intake (Kola et al., 2008).
Interleukin-6
IL-6 is produced and released by skeletal myocytes in response
to contraction. Basal IL-6 release from soleus was increased in
AMPKa2 knockdown and AMPKa1 knockout mice, suggesting
AMPKparticipates in the regulation of IL-6 release from oxidative
muscle. Conversely, IL-6 release from soleus was reduced 45%
when AMPK was activated by A-769662 (a direct activator of
AMPK, see below). These observations suggest a role of AMPK
in the regulation of IL-6 release from oxidative skeletal muscle
(Glund et al., 2008). IL-6 also rapidly and markedly increased
AMPK activity in myotubes, enhancing fatty acid oxidation as
well as basal and insulin-stimulated glucose uptake (Carey et al.,
2006). Correspondingly, IL-6 deficiency is associated with a
decrease in AMPK activity (Kelly et al., 2004).
Natural Products
A number of natural products, including alkaloids, bitter melon
extracts, etc., have been found to have effects on AMPK activa-
tion. Epigallocatechin-3-gallate, a main catechin of green tea,
suppressed hepatic gluconeogenesis by AMPK activation,
mediated by CaMKK (Collins et al., 2007).
Berberine, an alkaloid isolated fromRhizomacoptidis, is anoral
antihyperglycemic agent. Berberine caused inhibition of mito-
chondrial function that increases the AMP/ATP ratio, which could
explain the activation of the AMPK pathway by berberine as well
as its beneficial effects in the treatment of diabetes and obesity in
animal models (Yin et al., 2008), a hypothesis consistent with and
confirmed by additional in vivo studies (Turner et al., 2008).410 Cell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc.
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a-Lipoic acid (a-LA) is a cofactor of mitochondrial enzymes that
play key roles in catalyzing the decarboxylation of a-keto acids.
a-LA decreased hypothalamic AMPK activity and caused
profound weight loss in rodents by reducing food intake and
enhancing energy expenditure (Kim et al., 2004). In peripheral
tissues, a-LA activated AMPK in skeletal muscle as well as endo-
thelial cells. a-LA also increased insulin-stimulated whole-body
glucose uptake and fatty acid oxidation in obese rats (Lee
et al., 2005). However, a-LA-stimulated glucose oxidation in iso-
lated working rat hearts was independent of AMPK activation
(Onay-Besikci et al., 2007).
Resveratrol/SIRT1
SIRT1 is amember of a highly conservedgene family (sirtuins) en-
coding NAD(+)-dependent deacetylases. LKB1was shown to be
acetylated inHEK293T cells,mousewhite adipose tissue, and rat
liver. In vivo, total LKB1 lysine-acetylation was decreased by
60% in the liver of 48 hr starved rats compared to starved-refed
rats, and this was associated with modest but significant
increases inbothLKB1andAMPKactivities, establishingamech-
anistic link between LKB1 deacetylation by SIRT1 and LKB/
AMPK activation (Lan et al., 2008). In parallel, SIRT1 activation
by resveratrol and the synthetic polyphenol S17834, while
increasing SIRT1 deacetylase activity, also increased LKB1
phosphorylation at Ser428 and AMPK activity (Hou et al., 2008).
Resveratrol analogs, such as combretastatin A-4 (CA-4), can
function similarly as resveratrol and activate AMPK (Zhang
et al., 2008).
Activation of AMPK by Direct Activators
As can be inferred from the discussions above, direct activators
of AMPK that act without increasing cellular AMP/ATP ratios are
being pursued as novel therapeutics. By definition, a direct acti-
vator should bind directly to the three subunits (a, b, or g) of the
AMPK holo enzyme. Summarized below are two examples of
direct AMPK activators (Cool et al., 2006; Pang et al., 2008).
A-769662
A-769662 is a recently identified thienopyridine family of AMPK
activators (Cool et al., 2006). It acts by directly stimulating
partially purified rat liver AMPK (EC50 = 0.8 mM) and inhibiting
fatty acid synthesis in primary rat hepatocytes (IC50 = 3.2 mM).
Short-term treatment of normal Sprague-Dawley rats with
A-769662 decreased liver malonyl-CoA levels and the respira-
tory exchange ratio, VCO2/VO2, indicating an increased rate of
whole-body fatty acid oxidation. Treatment of ob/ob mice with
A-769662 decreased hepatic expression of PEPCK, G6Pase,
and FAS; lowered plasma glucose by 40%; reduced body-
weight gain; and significantly decreased both plasma and liver
triglyceride levels.
How does A-769662 activate AMPK? When AMPK is in the
inactive conformation, ATP is bound to the g subunit, and
Thr172within the catalytica subunit is freely accessible toprotein
phosphatases and is maintained predominantly in the unphos-
phorylated form. Similar to AMP, A-769662 activates AMPK
both allosterically and by inhibiting dephosphorylation of AMPK
on Thr172. In contrast, mutation of Ser108 in the carbohydrate-
bindingmodule (CBM) of the b subunit to alanine reduces activa-
tion of AMPK by A-769662 but not by AMP. However, AMP
bindingof theg subunit and the subsequent autophosphorylationof Ser108 is not sufficient to maintain the conformation of AMPK
in the active form (Goransson et al., 2007; Sanders et al., 2007a).
Using recombinant enzyme preparations, it has been reported
thatA-769662exclusively activatesAMPKcomplexes containing
the b1 subunit (Scott et al., 2008), and activation of AMPK by
A-769662 involves an interaction between the b subunit CBM
and residues from the g subunit that are not involved in AMP
binding. Intriguingly, the CBM also binds glycogen, which then
interferes with AMPK activation by LKB1 or CamKKb as well as
allosterically inhibits the activity of AMPK (McBride et al., 2009).
It remains to be determined if A-769662 also alters the interaction
of CBM with glycogen.
Compared to ZMP and AMP, A-769662 has improved speci-
ficity for AMPK over other enzymes. On the other hand, a recent
paper highlighted an off-target activity for the compound being
inhibition of the 26S proteasome (IC50 = 62 mM) (Moreno et al.,
2008). Using hepatocytes generated from AMPKb1 null mice, it
was observed that A-769662 retained its glucose-lowering effect
independent ofAMPKactivation, suggesting additional off-target
activity of A-769662 (Scott et al., 2008).
PT1
Based on a previous report that inactive mammalian AMPKa1
catalytic subunit contains an autoinhibitory domain, screening
of a chemical library with inactive human a1 (residues 1–394)
led to the identification of a novel small molecule activator, PT1,
which allosterically activated AMPKa1 (1–394), a1 (1–335), a2
(1–398), and a1b1g1 in vitro and promoted phosphorylation of
AMPK and ACC in L6 myotubes and HeLa cells without an
increase in cellular AMP/ATP ratio (Pang et al., 2008). Modeling
studies revealed that PT1 may interact with AMPKa1 near the
autoinhibitory domain and directly relieve autoinhibition (Pang
et al., 2008). The in vivo activity of PT1 as well as the potential
of this lead structure to be further developed into a candidate
for testing in humans remain unknown at present.
Insights of AMPK Activation by Small Molecule Direct
Activators from Structural Studies
Prior crystallographic studies with fission yeast AMPK revealed
a single site in the g subunit that binds either ATP or AMP within
its Bateman domain B (Townley and Shapiro, 2007). However,
crystal structures of a heterotrimeric regulatory core fragment
from Schizosaccharomyces pombe AMPK in complex with
ADP, ADP/AMP, ADP/ATP, and ZMP provided new insight that
the structure of Schizosaccharomyces pombe AMPK embraces
two moles of ADP by its g subunit, suggesting a possible role for
ADP in regulating AMPK response to changes in cellular energy
status (Jin et al., 2007).
The activation of AMPK by A-769662, PT1, and AMP is sche-
matically shown in Figure 4. Structural studies should lead to
a more informed strategy in the screening and design of more
potent AMPK activators.
Challenges of Development of AMPK Activators
as a Therapy
Given the aforementioned critical actions of AMPK on glucose
and lipid metabolism and the encouraging data from indirect
as well as direct activators of AMPK in preclinical setting, target-
ing AMPK activation appears to be an attractive therapeutic
strategy for the treatment of T2DM and related metabolic disor-
ders. However, the following critical issues and challenges willCell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc. 411
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Shown are examples of AMPK activation by direct small molecule activators that act on the a (PT1), b (A-769662), or g (AMP) subunits, illustrating the possibility of
targeting a subset of or all AMPK complexes with activators.need to be fully considered in order to realize the potential of this
target.
What Are the AMPK Isoforms that Need to Be Targeted?
One major challenge in developing an AMPK activator is the
issue of isoform specificity. Given the possibility that 12 AMPK
complexes can form in vivo and that not a single subunit is
shared among all 12 complexes, it is a tremendous task to
develop a pan-activator, which might be required for efficacy
in preclinical species and in humans. The observation that PT1
can activate both a1 and a2 (Pang et al., 2008) suggests that it
is feasible to activate all 12 AMPK complexes by a single
compound. However, it is not clear whether all 12 AMPK
complexes could be or need to be activated to the same degree
in order to realize the maximum benefits of AMPK activation
in vivo. Furthermore, it is conceivable that distinct subunit distri-
butions exist in different tissues of a given species. In addition,
AMPK complex composition in a given tissue (e.g., liver) across
different species could be different. This complexity makes it
highly challenging to translate the in vivo efficacy of an AMPK
activator in preclinical models to humans.
Are There Liabilities of Systemic AMPK Activation?
Agents that decrease the activity of AMPK in hypothalamus
reduce food intake (Minokoshi et al., 2008), while agents that
increase the activity of AMPK in hypothalamus may increase
food intake as well as hepatic glucose output in rodents (Kubota
et al., 2007; McCrimmon et al., 2008). These observations raise
the question of whether a brain penetrant direct AMPK activator
may cause undesired consequences. However, genetic studies
led to a more complex picture of the effect of AMPK in the brain.
Mice lacking AMPKa2 in different brain regions developed oppo-412 Cell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc.site phenotypes: knockout of AMPKa2 in pro-opiomelanocortin
neurons caused obesity while mice with knockout of the same
gene in agouti-related protein neurons developed an age-depen-
dent lean phenotype. Interestingly, neurons from both lines of
knockoutmice exhibited normal leptin or insulin actionbut lacked
the responses to alterations in extracellular glucose levels. These
findings suggest that while AMPK plays a key role in hypotha-
lamic function, it does not act as a general sensor and integrator
of energy homeostasis in this region of the hypothalamus (Claret
et al., 2007). Nonetheless, these data caution against developing
AMPK activators that cross the blood-brain barrier.
Wolff-Parkinson-White (WPW) syndrome is manifested mainly
as a cardiac conduction system defect. While the genetic basis
for the majority of patients afflicted with WPW syndrome has
not been delineated, mutations in the AMPKg2 subunit have
been identified in a small percentage of patients with the
syndrome (Arad et al., 2007). These mutations cause disparate
effects on AMPK activity, and it is uncertain whether the effects
of mutations on cardiac AMPK activity are the cause of WPW
syndrome (Young, 2008). A recent report showed that macro-
phage migration inhibitory factor, an upstream regulator of
inflammation, was released in the ischemic heart, where it stimu-
lated AMPK through CD74, promoted glucose uptake, and pro-
tected the heart during ischemia-reperfusion injury (Miller et al.,
2008). While unsettled (Akman et al., 2007; Luptak et al., 2007),
the effect of AMPK activation on cardiac function will need to
be closely monitored.
The effects of AMPK activation in pancreatic islets and
adipose tissue are less well characterized. Expression of consti-
tutively active AMPK induced apoptosis in clonal MIN6 b cells
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ReviewFigure 5. Multiple Effects of AMPK Activation in Liver and Muscle Leading to Improved Metabolic Control
These effects include modulation of lipid metabolism, mitochondrial biogenesis, mimicking the beneficial effects of exercise, improvement in insulin sensitivity,
and reduction in blood glucose. The stick figure in the center of the illustration denotes the AMPK complex containing the a, b, and g subunits. The complex is
activated by phosphorylation and binding to AMP.and CD1 mouse pancreatic islets (Riboulet-Chavey et al., 2008).
In adipose tissue, AICAR-induced AMPK activation suppressed
the activity of HSL but promoted a 4-fold increase in ATGL
content in adipocytes (Gaidhu et al., 2008). The effect of activa-
tion of AMPK by specific activators in adipose tissue and in islet
will warrant further investigation.
Should a Strategy of Tissue-Selective AMPK Activation
Be Employed?
Given the potential adverse effects that may be associated with
sustained systemic pharmacological activation of AMPK, an
intriguing concept is to target AMPK activation in specific
tissues. As discussed above, liver and skeletal muscle are the
twomain tissues in which activation of AMPKwould be expected
to lead to improved insulin sensitivity and whole-body energy
homeostasis.
There are a number of factors that can be exploited to attempt
to enrich liver exposure of AMPK activators relative to extrahe-
patic tissues. In particular, the liver is rich in metabolic enzymesand uptake transporters, and it is the first organ exposed to
compounds after adsorption in the gastrointestinal tract. A
prerequisite for any successful liver targeting strategy is that
passive diffusion out of the liver be minimized, since this
opposes the desired gradient and is likely to mirror passive diffu-
sion into other tissues. One particularly attractive strategy is the
development of cell-permeable prodrugs that are cleaved or
oxidized by metabolic enzymes (CYP isozymes, esterases,
amidases, etc.) to generate less cell-permeable active species.
Another approach is exemplified by metformin, where organic
cation transporter 1 is responsible for its hepatic uptake as
well as playing a role in its intestinal uptake (Wang et al., 2002).
Liver-targeted AMPK activators may provide an effective means
to avoid exposure to other tissues, while they will limit the poten-
tial to harness the benefit of AMPK activation in skeletal muscle.
Approaches relying on drug distribution to skeletal muscle
seem unlikely to be successful, given the high level of cardiac
perfusionand the lackof known, suitable, skeletalmuscle-specificCell Metabolism 9, May 6, 2009 ª2009 Elsevier Inc. 413
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Reviewuptake transporters. Themost viable strategywould appear to be
targeting specific AMPK complexes that are enriched in skeletal
muscle. In this regard, theAMPKa2b2g3 is particularly interesting,
since this g3-containing complex is expressed only in skeletal
muscle, and it is the only complex that is predominately activated
during high-intensity exercise in humansubjects (Birk andWojtas-
zewski, 2006). The need to develop complex-specific AMPK acti-
vators requires expression of all 12 possible complexes in order to
identify and optimize selective compounds.
Will AMPK Activation Result in Glucose Lowering
in Humans?
The test of activating AMPK as a therapeutic approach requires
a proof of concept study for glucose-lowering efficacy in the
clinic. It is not clear howmuch activation relative to that achieved
by AMP is needed for efficacy. Furthermore, it needs to be estab-
lished whether continuous activation is desirable or whether
intermittent activations of AMPK mimicking bouts of exercise
will yield greater efficacy in the control of glucose homeostasis.
Much of the preclinical validation guiding the development of
AMPK activators is from rodent genetic models as well as the
use of nonselective activators such as AICAR that also affect
many AMP-modulated metabolic enzymes, including fructose
1,6-bisphosphatase and glycogen phosphorylase. In addition,
because animal models deficient in all AMPK complexes, such
as double knockout of a1 and a2 subunits of AMPK, are not
viable, it is not feasible to test direct systemic AMPK activators
in thesemodels to definitively establish that the beneficial effects
are on target. In this regard, mice with liver-specific double
knockout of a1 and a2 are viable (Guigas et al., 2006), providing
a possible means to test the on-target activity of liver-targeted
AMPK activators. As a novel therapy, the net efficacy of an
AMPK activator relative to other glucose lowering agents will
also need to be defined. Finally, since metformin is a first-line
therapy in the treatment of diabetes, it will be advantageous if
an AMPK activator is combinable with or has advantage over
metformin. While these questions pose significant challenges
in developing a direct AMPK activator for the treatment of
T2DM and the metabolic syndrome, the potential benefits of
AMPK activation will make this task ultimately a rewarding
journey, as depicted in Figure 5.
Future Prospects
Intense research in recent years has revealed the critical roles
that AMPK plays in modulating an ever-expanding array of bio-
logical pathways. The broad spectrum of activities of AMPK in
lipid and glucose metabolism makes it a very attractive target
for drug discovery. The feasibility of developing potent and selec-
tive activators has begun to emerge, and the recent preliminary
proof of concept in preclinicalmodels suggests that there is great
hope for therapeutic use of AMPK activators in humans afflicted
with T2DM and related metabolic disorders. With the challenges
faced by targeting this complex enzyme, the question is not
whether but when this possibility will be realized in the clinic.
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